Search research articles
Contact Us
Filters
Showing results (71-80 of 95) with videos related to
Page
of 10
Sort By:
Signal Transduction and Targeted Therapy
|
January 17, 2025
Safety and efficacy of trifluridine/tipiracil +/- bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial
Marion Thibaudin, Nicolas Roussot, Chloé Burlot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 19, 2018
Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9)
Thomas Aparicio, Francois Ghiringhelli, Valérie Boige, et al.
Frontiers in Oncology
|
September 19, 2022
Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma
Stefano Kim, Jihane Boustani, Dewi Vernerey, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 30, 2017
Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects
Simon Pernot, Cecile Badoual, Magali Terme, et al.
Journal for Immunotherapy of Cancer
|
June 8, 2023
Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop
Guy Travis Clifton, Mace Rothenberg, Paolo Antonio Ascierto, et al.
Journal for Immunotherapy of Cancer
|
June 22, 2026
IL-10 secretion by CD8 T cells orchestrates early NK cell recruitment and antitumor immunity after anti-VEGFR-2/PD-1 therapy
Mannon Geindreau, Cassandre Pignol, Loïs Coënon, et al.
Future Oncology (London, England)
|
November 12, 2024
Phase I/II study of trifluridine/tipiracil plus XB2001 versus trifluridine/tipiracil in metastatic colorectal cancer
Jean-David Fumet, Nicolas Roussot, Aurélie Bertaut, et al.
Frontiers in Oncology
|
August 5, 2022
A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 T<sub>H</sub>1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study
Magali Rebucci-Peixoto, Angélique Vienot, Olivier Adotevi, et al.
JTO Clinical and Research Reports
|
October 1, 2025
Evaluation of the Safety, Pharmacokinetics, and Antitumor Activity of Tusamitamab Ravtansine in Patients With Nonsquamous NSCLC With High or Moderate Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5
Anas Gazzah, Charles Ricordel, Antoine Italiano, et al.
Cancers
|
June 4, 2020
Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma
Julie Niogret, Emeric Limagne, Marion Thibaudin, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 95) with videos related to
Sort By:
Page
of 10
Signal Transduction and Targeted Therapy
|
January 17, 2025
Safety and efficacy of trifluridine/tipiracil +/- bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial
Marion Thibaudin, Nicolas Roussot, Chloé Burlot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 19, 2018
Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9)
Thomas Aparicio, Francois Ghiringhelli, Valérie Boige, et al.
Frontiers in Oncology
|
September 19, 2022
Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma
Stefano Kim, Jihane Boustani, Dewi Vernerey, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 30, 2017
Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects
Simon Pernot, Cecile Badoual, Magali Terme, et al.
Journal for Immunotherapy of Cancer
|
June 8, 2023
Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop
Guy Travis Clifton, Mace Rothenberg, Paolo Antonio Ascierto, et al.
Journal for Immunotherapy of Cancer
|
June 22, 2026
IL-10 secretion by CD8 T cells orchestrates early NK cell recruitment and antitumor immunity after anti-VEGFR-2/PD-1 therapy
Mannon Geindreau, Cassandre Pignol, Loïs Coënon, et al.
Future Oncology (London, England)
|
November 12, 2024
Phase I/II study of trifluridine/tipiracil plus XB2001 versus trifluridine/tipiracil in metastatic colorectal cancer
Jean-David Fumet, Nicolas Roussot, Aurélie Bertaut, et al.
Frontiers in Oncology
|
August 5, 2022
A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 T<sub>H</sub>1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study
Magali Rebucci-Peixoto, Angélique Vienot, Olivier Adotevi, et al.
JTO Clinical and Research Reports
|
October 1, 2025
Evaluation of the Safety, Pharmacokinetics, and Antitumor Activity of Tusamitamab Ravtansine in Patients With Nonsquamous NSCLC With High or Moderate Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5
Anas Gazzah, Charles Ricordel, Antoine Italiano, et al.
Cancers
|
June 4, 2020
Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma
Julie Niogret, Emeric Limagne, Marion Thibaudin, et al.
Page
of 10